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Abstract
Defects in nuclear-encoded proteins of the mitochondrial translationmachinery cause early-onset and tissue-specific deficiency
of one or more OXPHOS complexes. Here, we report a 7-year-old Italian boy with childhood-onset rapidly progressive encepha-
lomyopathy and stroke-like episodes. Multiple OXPHOS defects and decreasedmtDNA copy number (40%) were detected in
muscle homogenate. Clinical features combined with low level of plasma citrulline were highly suggestive of mitochondrial en-
cephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome, however, the commonm.3243A>Gmutation was ex-
cluded. Targeted exome sequencing of genes encoding the mitochondrial proteome identified a damaging mutation, c.567G>A,
affecting a highly conserved amino acid residue (p.Gly189Arg) of the MRM2 protein.MRM2 has never before been linked to a hu-
man disease and encodes an enzyme responsible for 2’-O-methyl modification at position U1369 in the humanmitochondrial
16S rRNA. We generated a knockout yeast model for the orthologous gene that showed a defect in respiration and the reduction
of the 2’-O-methyl modification at the equivalent position (U2791) in the yeast mitochondrial 21S rRNA. Complementation with
themrm2 allele carrying the equivalent yeast mutation failed to rescue the respiratory phenotype, which was instead com-
pletely rescued by expressing the wild-type allele. Our findings establish that defective MRM2 causes a MELAS-like phenotype,
and suggests the genetic screening of theMRM2 gene in patients with a m.3243A>G negative MELAS-like presentation.
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Introduction
Mitochondria are eukaryotic intracellular organelles that play a
central role in cellular metabolism by performing oxidative
phosphorylation (OXPHOS) (1). Unique features of mitochondria
are the presence of a 16.6 kb circular DNA molecule (mtDNA),
encoding 22 tRNA, 2 rRNA and 13 protein subunits of the
OXPHOS system, and intra-mitochondrial replication and trans-
lational machineries. Mitochondrial protein synthesis requires
a number of structural and regulatory proteins, including
mitoribosomal proteins, translation factors, aminoacyl tRNA
synthetases, RNA processing enzymes, and other auxiliary
factors. All of them are encoded by the nuclear DNA and
translocated into mitochondria upon their synthesis in the
cytoplasm (2).
Post-transcriptional chemical modifications of RNA, collec-
tively referred to as epitranscriptome, are required for proper
structure and function of RNA. Mitochondrial transcripts are
also subject to enzymatic nucleotide modifications in human
mitochondria. Systematic analysis of all bovine mitochondrial
tRNAs (mt-tRNAs) reveled that approximately 7% of their resi-
dues undergo post-transcriptional modification, with the ma-
jority of these modifications being conserved in the human
mitochondrial epitranscriptome (3,4). Also, a set of well-
conserved chemical modifications to the small (12 S) and the
large (16S) mitochondrial ribosomal RNAs (mt-rRNAs) has been
identified and several proteins responsible for introducing these
modifications have been characterized (5). In 12S mt-rRNA,
TFB1M is responsible for dimethylation of adenines A936 and
A937 (6,7), whereas NSUN4 methylates cytidine at position 841
(8). The 16S mt-rRNA is also a substrate for one pseudouridyla-
tion (Psi1397), potentially introduced by RPUSD4 (9,10). Very re-
cently identified modification, m1A947, has been shown to be
introduced by TRMT61B (11). Finally, a group of closely related
2’-O-ribose methyltransferases, MRM1, MRM2 (FtsJ2) and MRM3
(RNMTL1) modify three nucleotide positions of the peptidyl
transferase centre of 16S mt-rRNA, G1145, U1369 and G1370, re-
spectively (12,13). Inactivation of the mt-rRNA modifiers often
result in the inhibition of mitochondrial translation and/or
mitoribosome biogenesis, however, the exact role of these RNA
modifications is largely unknown.
Defects in mitochondrial translation due to problems in
post-transcriptional mitochondrial (mt-) RNA nucleolytic pro-
cessing, nucleotide modifications, stability or aminoacylation
have been identified in patients with combined or isolated
(complex I or IV) OXPHOS deficiencies and variable clinical phe-
notype. The central nervous system and heart are the most af-
fected tissues with the majority of patients presenting with
leukoencephalopathy, for example, TRNT1, TRIT1, NSUN3,
TRMT5, DARS2, RARS2, EARS2, MTFMT (14–23) or hypertrophic
cardiomyopathy for example, MTO1, ELAC2, GTPBP3, AARS2
(24–27). Neurological symptoms include developmental delay,
ataxia, seizures, hypotonia, spasticity, and peripheral neuropa-
thy. Hematological, hepatic and renal involvement has also
been described in isolation and in multisystemic clinical syn-
dromes, for example, TRMU, PUS1, YARS2, SARS2, HARS2,
LARS2 (28–32).
Here, we report for the first time that defects in the nucleo-
tide modification of mitochondrial ribosomal rRNA can lead to
human disorders of mitochondrial respiration. We describe ho-
mozygous mutations inMRM2 gene encoding the mitochondrial
16S rRNA methyltransferase MRM2 in a patient with MELAS-like
encephalomyopathy, multiple OXPHOS deficiency and reduc-
tion of mtDNA copy number.
Results
Subject
A 7-year-old boy born at term after uneventful pregnancy to
non-consanguineous Italian parents presented at 8months of
life with developmental delay and a complex movement disor-
der characterized by generalized dyskinesia, featuring chorea,
ballismus, also involving the cervical and oropharyngeal mus-
cles, not responsive to levodopa and carbidopa treatment.
Cerebrospinal fluid neurotransmitters and brain MRI (18
months of age) were unrevealing. The clinical course was stable
in the first stage, but no motor or language milestones were ac-
quired. At 4 years of age, the boy exhibited an acute deteriora-
tion during a febrile respiratory infection. He was admitted to
pediatric intensive care for recurrent episodes of convulsive
status epilepticus which were associated with multiple stroke
lesions on brain MRI. Epilepsy proved refractory to combined
anticonvulsant treatment and further complicated by mixed ac-
idosis. He required induction of pharmacological coma, trache-
ostomy and nasogastric tube feeding. Metabolic workup
including plasma aminoacids, acylcarnitine and lactate, urinary
organic acids and orotic acid was unrevealing except for low
levels of citrulline (9 lmol/l; n.r.17-53). Brain MRI on the 2nd day
after the first episode of status epilepticus showed a focal lesion
in the left parieto-temporal- occipital region with a ring of
edema and restriction of diffusion. Cerebellar atrophy was also
present. Magnetic resonance spectroscopy (MRs) with ROI
(Region Of Interest) within the lesion showed a peak of lactate
and reduction of NAA/Cr (Fig. 1A). Follow-up MRI (on day 10)
confirmed the stroke-like lesion in the parieto-occipital region
and revealed additional lesions in the right parsagittal frontal
and fronto-insular cortex (Fig. 1B). MRs showed normalization
of the lactate peak. The patient was able to overcome the acute
episode, however, his neurological conditions were severely
compromised with spastic quadriparesis, a complex dyskinetic
movement disorder and epilepsia partialis continua resistant to
anticonvulsant polytherapies. Repeat brain MRI at 1 year of
follow-up showed severe cerebral and cerebellar atrophy
(Fig. 1C). The clinical course was complicated by recurrent epi-
sodes of liver failure, hyperammonemia and rhabdomyolysis
triggered by infections. He died at 7 years of age when a febrile
illness progressed to sepsis. Brain MRI imaging, together with
the clinical picture and the low level of plasma citrulline, was
suggestive of MELAS. However, the common m.3243A>G mu-
tation in the mt-tRNALeu was excluded. Mitochondrial respira-
tory chain activities on muscle homogenate revealed multiple
OXPHOS defects with Complex I and IV being severely affected
while other complexes were at borderline level (Table 1).
Quantitative PCR with DNA extracted from muscle revealed
40% of residual mtDNA copy number.
Target exome sequencing revealed defect inMRM2 gene
A homozygous missense variant Chr7: 2274933C>T (NM_013393:
c.567G>A) in the MRM2 gene (encoding mitochondrial rRNA
methyltransferase 2) has been identified. This variant has never
been observed in the ExAC database and affects amino acid
p.Gly189Arg (NP_037525). The Gly189 residue is extremely highly
conserved across evolution, and is identical in 41/44 aligned
vertebrate species as well as in yeast S. cerevisiae (Mrm2p) and
even E. coli (RrmJ) (Fig. 2A). The variant was predicted deleterious
by Polyphen algorithm (http://genetics.bwh.harvard.edu/pph/).
Analysis of the run of homozygosity (ROH) for the MRM2: p.G189R
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homozygous variant showed a ROH of at least 16kb in length.
Sanger sequencing confirmed the mutation to be homozygous in
the proband’s DNA and heterozygous in both parents’ DNA
(Fig. 2B).
In the human MRM2 structure (PDB ID: 2NYU) Gly189 is not
located in the vicinity of the site involved in S-adenosyl-methio-
nine (SAM) binding and catalysis (Fig. 2C). We have modeled the
p.Gly189Arg mutation into the MRM2 tridimensional structure
using the wild-type crystal structure as a template. Based on
structural analysis, we predict that the mutation of Gly189 to an
arginine results in a potential new interaction with Asp149
(Fig. 2C). In the wild-type protein Asp149 forms a bond with
Arg75. Although the role of Asp149 and Arg75 in the function of
MRM2 is unknown, the potential Arg189-Asp149 interaction
might have knock-on effects on the global structure of the pro-
tein reducing its catalytic function.
Functional studies confirmed pathogenicity of
the mutation
Mitochondrial respiratory chain activities in fibroblasts cultured
in typical media revealed increased activity of citrate synthase
(CS) and succinate dehydrogenase (Complex II), both indicators
of mitochondrial mass. Normal but borderline activity of
Complex I (NADH-CoQ1 reductase), III (DBH2 Cytochrome C
Reductase) and IV (Cytochrome oxidase), were detected when
normalized to CS. Galactose-media stress inhibits mitochon-
drial respiration and consequently can alter mitochondrial
mass by inducing mitophagy and causing depletion of mito-
chondrial mass in patient’s fibroblasts (33). Similarly to previous
reported cases, a profound reduction of mitochondrial mass
with accompanied reduction of respiratory chain complex
activities was identified when the patient fibroblasts were
grown in media containing galactose as a sole carbon source
(Supplementary Material, Fig. S1A). The MRM2 gene was
Figure 1.MRI brain imaging. (A) MRI abnormalities in the acute stage (48h from status epilepticus). A1: Sagittal T2 weighted image showing initial signs of cerebellar at-
rophy. A2: Axial T2-weighted image showing hyperintensities in the left parieto-temporo-occipital area. A3: Spectroscopy analysis with ROI in the acute lesion showing
reduction of NAA/CR, increase of Cho/CR and lactate peak. (B) Follow-up MRI (15 days): sagittal (B1) and coronal (B2) axial T2 (B2 and B3), FLAIR (B4) and coronal T2 (B5)
T2-weighted images showing additional bilateral frontal lesions and cerebral and cerebellar atrophy. (C) MRI abnormalities in the chronic stage (one year after acute
onset): Sagittal T1 (C1), axial T2 (C2 and C3), FLAIR (C4) and coronal T2 (C5) images showing severe progression of cerebral and cerebellar atrophy.
Table 1. Mitochondrial Respiratory chain activities in muscle
homogenate
Enzyme normalized to CS Patient Normal range
Cytochrome c oxidase (IV) 48 120–220
Succinate-cytochrome c reductase (IIþIII) 17.8 15–28
DBH2-cytochrome c reductase (III) 61 60–100
NADH-CoQ1 reductase (I) 6.7 13–24
Succinate dehydrogenase (II) 10.8 10.7–17.4
Citrate synthase (nmol/min mg)(CS) 105 80–210
Defective values are highlighted in bold.
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expressed normally in patient fibroblasts as demonstrated by
analyzing mRNA level (by qRT-PCR) and steady-state level of
the MRM2 protein (by Western blot immunovisualization)
(Supplementary Material, Fig. S1B and C).
It has been previously shown that the MRM2 methyltransfer-
ase introduces 2’-O-methylation at the U1369 (Um1369) of
mitochondrial 16S rRNA and that its inactivation leads to a reduc-
tion of the intra-mitochondrial translation (12,13). Therefore, we
set out to determine whether the MRM2 variant identified in the
patient results in diminished levels of Um1369 in 16S mt-rRNA
and may impair mitochondrial translation. The detection of Um
in RNA can be achieved by reverse transcription primer extension
A
B C
Figure 2. Detection of the p.Gly189Arg MRM2 variant and its implications on protein structure. (A) Sequence alignment of MRM2 with homologs in E. coli and yeast
S. cerevisiae. Conserved residues important for catalysis are coloured - yellow (Lys59), red (Asp154), green (Lys194) and purple (Glu229) (34). The mutation p.Gly189Arg is
in blue. Brown dots above the sequence identify residues involved in SAM-binding. (B) Sanger sequencing results confirming segregation of the p.Gly189Arg variant.
The c.567G>Amutation site is indicated by a blue frame. Protein sequence of the analyzed DNA fragment given below the chromatograms. GGG – Gly codon, AGG – Arg
codon. (C) Modeling of the three-dimensional structure of human MRM2 with the p.Gly189Arg amino acid substitution. (i) Models of wild-type MRM2 and the
p.Gly189Arg mutant with SAM in the active site were generated on the template of crystal structure (PDB ID 2NYU). The magnified regions show potential new amino
acid interactions in the mutant protein (residue numbers are based on the human MRM2 sequence). SAM is colored pink.
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(RT-PEx). This approach relies upon pausing of the reverse tran-
scriptase at a 2’-O-methylation site (13,18). To normalize RNA in-
put, RT-PEx was performed in the absence of dGTP to cause
stalling shortly downstream from the modification site (Fig. 3A).
RT-PEx of a radioactively labeled primer annealing downstream of
Um1369 using total RNA did not demonstrate any detectable
changes in pausing at Um1369 in the patient sample as compared
to the control samples (Fig. 3B and C). In further experiments, we
investigated the mtDNA-encoded OXPHOS proteins by analyzing
the steady state levels by western blotting and metabolic labeling
using assay [35S]-methionine. We did not observe any detectable
changes in mitochondrial translation (Fig. 3D and Supplementary
Material, Fig. S1D). Taken together, our data suggest that patient-
derived fibroblast cells did not show the disease phenotype, con-
sistent with this tissue not being affected.
In order to prove the pathogenicity of the mutation, we mod-
eled the identified gene defect in yeast S. cerevisiae. The sequences
of yeast and human MRM2 proteins are well conserved (Fig. 2A)
and modify the corresponding residues in the large mitochondrial
rRNA (13,34). We analyzed the yeast Mrm2p p.Gly259Arg substitu-
tion corresponding to the human p.Gly189Arg variant. Previous
data indicated that the Mrm2p-null strain (mrm2D) shows
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Figure 3. Studies of 16S mt-rRNA modification and mitochondrial translation in patient fibroblasts. (A) A radioactively-labeled, complementary primer (black arrow) is
annealed to the large 16S rRNA and subjected to a reverse transcriptase primer extension (RT-PEx) reaction. The presence of Um1369 (modified by MRM2, blue arrow)
and Gm1370 (modified by MRM3 (13) - grey arrow) results in RT-PEx pausing, producing shorter products. Reduced levels of Um1369 and Gm1370, however, lead to the
extension reaction progress until stalling due to the lack of a dGTP (green), producing a longer product. (B) Representative PAGE separation and detection of RT-PEx
products preformed on RNA extracted from control and patient fibroblasts (G189R), with a densitometric analysis presented to the right. (C) Quantification values rep-
resenting the ratio of the intensity of the RT-PEx product specific for 2’-O-methylation (Um1369 or Gm1370) to the intensity of the dGTP-induced stalling. (D) Metabolic
labelling of mitochondrial translation products with [35S]-methionine in control and patient fibroblasts (G189R). CBS: Coomassie blue stained gel as loading control.
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thermosensitive respiratory deficiency (34). We have analyzed the
mrm2D strain and confirmed this phenotype, detecting that the
respiration is also affected in the permissive temperature (Fig. 4A).
We rescued the respiratory defect by expression of a wild-type
yeastMRM2 allele (Fig. 4A). However, expression of the allele carry-
ing the p.Gly259Arg mutation did not lead to a full recovery of the
decreased mitochondrial respiratory activity (Fig. 4A). Next, we an-
alyzed if the yeast Mrm2p p.Gly259Arg variant results in dimin-
ished Um2791 modification in yeast mitochondrial 21S rRNA that
corresponds to Um1369 in human 16S mt-rRNA (13). We have
adapted the RT-PEx approach as described above by using a primer
that annealed downstream from the Um2791 site of 21S mt-rRNA
(Fig. 4B). Performing the reaction without dTTP allowed for normal-
izing the relative pausing on Um2791 to the RNA input. RT-PEx re-
actions performed on RNA samples from the mrm2D strain
demonstrated very low 2’-O-methyl pausing at U2791, consistent
with the lack of the modification of this residue in the absence
of Mrm2p (Fig. 4C–E). Expression of a wild-type MRM2 allele re-
stored the Um2791 modification, whereas expression of the allele
carrying the p.Gly259Arg mutation did not result in similar detect-
able levels of Um2791 (Fig. 4C–E). In conclusion, these data are in
agreement with a causal role for the p.Gly259Arg MRM2 variant in
the aberrantmt-rRNAmodification and oxidativemetabolism defi-
ciency in the patient.
Discussion
Stroke-like episodes have been recognized as a distinctive fea-
ture of maternally-inherited mitochondrial syndrome, MELAS
(mitochondrial encephalopathy with lactic acidosis and stroke-
like episodes), a multi-organ disease presenting with lactic acid-
emia and stroke-like episodes before age of 40 years, epilepsy,
dementia and mitochondrial myopathy (35). The disease is due
to mtDNA mutations in tRNA genes involved in the organelle
A
B
C D
E
Figure 4. Causal role of the p.Gly189Arg MRM2 variant in oxidative metabolism deficiency and mitochondrial rRNA modification. (A) Complementation assay in yeast.
Yeast MRM2 was cloned under its natural promoter upon PCR-amplification. PCR-based mutagenesis was performed to obtain the mrm2G259R mutant allele. The MRM2
and mrm2G259R alleles cloned into the monocopy pFL38 vector were introduced into a strain harboring a disruption of genomic MRM2 gene (mrm2D). EV denotes the
empty pFL38 vector control. Oxygen consumption rate was recorded on intact cells grown at 28 "C and 37 "C in synthetic complete medium without uracil, supple-
mented with 0.6% glucose. Values were normalized to the rate of oxygen consumption of the MRM2 transformant and represented as the mean of three independent
experiments. Error bars ¼ 1 SD, *P<0.05, ***P<0.001 with paired Student’s t-test. (B) A radioactively-labeled, complementary primer (black arrow) is annealed to the large
rRNA and subjected to a reverse transcriptase primer extension (RT-PEx) reaction. The presence of Um2791 results in RT-PEx pausing producing a shorter product
(blue). In the absence of Um2791, however, the extension progresses until stalling due to the lack of a dTTP (green), producing a longer product. (C) PAGE separation
and detection of RT-PEx products preformed on RNA extracted from the mrm2D yeast transformed with pFL38 (EV), MRM2 or mrm2G259R. (D) Densitometric analysis of
the RT-PEx experiment shown in (C). (E) Quantification values representing the ratio of the intensity of the RT-PEx product specific for Um2791 to the intensity of the
dTTP-induced stalling. Error bars ¼ 1 SD; n¼4, **P<0.01, with unpaired, two-tailed Student’s t-Test using the MRM2 sample.
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protein translation with the most common variant m.3243A>G
in the mt-tRNALeu. Energy depletion as well as NO (nitric oxide)
deficiency are responsible for the pathogenesis of the disease as
demonstrated by low plasma levels of an NO donor, citrulline,
and the potential therapeutic effect of citrulline and its metabo-
lite, arginine (36). Stroke-like episodes have been sporadically
described as additional neuroradiological and clinical features
in other mitochondrial disorders such as Alpers disease (37), co-
enzyme Q10 deficiency (38), 3-methylcrotonyl-CoA carboxylase
1 deficiency (39) and Leigh Syndrome French Canadian syn-
drome due to LRPRRC gene defect (40).
Here, we report a patient presenting with encephalopathy,
stroke-like episodes, lactic acidosis, hypocitrullinemia, and multi-
ple OXPHOS defects that are all clinical, biochemical and meta-
bolic hallmarks for a diagnosis of MELAS-like syndrome. Although
previously reported in isolated cases of MELAS syndrome (41–47),
the complex movement disorders with chorea and ballism and
the rapidly progressive clinical course with rhabdomyolysis and
multi-organs failure represent distinctive clinical features in our
case. Next generation sequencing withMitoExome sequencing ex-
cluded variants inmtDNA and identified a damaging homozygous
mutation in a nuclear-encoded protein MRM2 playing a role in the
mitochondrial protein translation machinery. Human MRM2 has
been described as a putative uridine 2’-O-methyltransferase for
the U1369 position of the mitochondrial 16S rRNA. Um1369 is lo-
cated in the peptidyl transferase center and is implicated in the
interaction of the ribosomewith an aminoacyl(A)-site tRNA. In ad-
dition, proteomic studies have demonstrated the role of MRM2 in
the assembly and/or stability of the large 39S mitoribosomal sub-
unit. The central role of MRM2 in the mitochondrial protein syn-
thesis is confirmed by the multiple OXPHOS defects and reduction
of mitochondrial translation and oxygen consumption rate in
siRNA knockdown cell lines (13). Primary fibroblasts derived from
the patient did not recapitulate the mitochondrial phenotypes ob-
served upon MRM2 RNAi. This might be related to remarkable
tissue-specificity observed in mitochondrial translational defects
(18) and other mitochondrial diseases (48). Nonetheless, the yeast
model showed the defect in cellular respiration and in modifica-
tion of the equivalent uridine, Um2971, of yeast mitochondrial
21S rRNA. Complementation with wild-type MRM2 allele rescued
both of these defects, however, they were still present when we
expressed the MRM2 variant harboring the yeast mutation corre-
sponding to the variant detected in the patient, confirming the
pathogenicity of the mutation (Fig. 4).
Defective mitochondrial translation, caused by mutations in
either the mitochondrial or nuclear genomes, is associated with
a diverse group of human disorders characterized by impaired
mitochondrial respiration. Within this group, an increasing
number of mutations have been identified in genes involved in
precursor mt-RNA processing (25,49,50) and in mt-tRNA epitran-
scriptome shaping (14,16–18,24,26,28,51). Most of them have
been found in pediatric patients with combined respiratory
chain activity defects by large gene screening with next genera-
tion exome sequencing (52,53). Clinical syndromes associated
with defects in mtRNAmetabolism are characterized by the var-
iable combination of encephalopathy, myopathy, sideroblastic
anemia, cardiomyopathy, renal or liver dysfunction. The central
and peripheral nervous systems are predominantly affected
with a generalized neuronal and/or myelin degenerative pro-
cess (TRNT1, TRIT1, NSUN3 and TRMT5) or with selective dam-
age of basal ganglia (GTPBP3) (54,55).
Here, we report for the first time, a MELAS-like clinical syn-
drome due to a nuclear-encoded protein, MRM2, further expanding
the clinical and genetic heterogeneity of mitochondrial disorders
and suggesting screening of MRM2 in patients with clinical and bio-
chemical characteristics of MELAS syndrome with unknown ge-
netic cause. Interestingly, a reduction in mtDNA copy number has
been identified in muscle homogenate of our patient. A 40% resid-
ual mtDNA level is considered above the defined threshold for
clinically-manifest mtDNA depletion (30%), but led us to hypothe-
size a secondary effect of the mutation on mtDNA replication.
However, further studies are needed to confirm this hypothesis
and explore a further, potential pathogenetic role in mitochondrial
diseases associated with impairedmtDNAmaintenance.
In conclusion, MRM2 is a new disease-causing gene in
mtDNA metabolism pathway that should be considered in the
differential diagnosis of childhood-onset epilepsia partialis con-
tinua and stroke-like episodes.
Materials and Methods
Targeted exome sequencing
With the approval of the Pediatric Ethics Committees from the
Tuscany Region and the informed consent of the parents of the
affected individual, we performed targeted next-generation
exome sequencing using the patient’s DNA in order to identify
the genetic basis of the disease. An in-solution hybridization
capture method (56) was used to target the MitoExome, corre-
sponding to nuclear exons encoding known or predicted mito-
chondrial proteins as well as the mitochondrial DNA (mtDNA),
which was then sequenced on the Illumina GA-II platform as
previously described (52). The MRM2 variant was confirmed by
direct Sanger sequencing exon 2 with the following primers:
FWD: 5’-gtgattctgagcgacatggc-3’; REV: 5’-atgactctttcctgctggct-3’
and standard PCR amplification with 30 cycle at Tm 59 "C.
Functional studies in patient-derived fibroblast cell line
Skin fibroblasts from the patient and controls were grown in
basal condition with high-rich glucose Dulbecco’s Modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 0.02% fungizone, and 1% penicillin-streptomycin or, under
stressing conditions, with RPMI 1640 glucose-free medium with
10% regular FBS, 25mM HEPES, 1.5mM GlutaMAXTM, 25mM ga-
lactose, 0.02% fungizone, and 1% penicillin-streptomycin.
Mitochondrial respiratory chain enzyme activities
Measurements were performed in cell lysate as previously de-
scribed (57).
MRM2mRNA expression
RNA was extracted using PureLink RNA Mini Kit (Ambion, Life
Technologies), treated with RNase-free DNase (Roche). cDNA
was obtained with the VILO RT-PCR kit (Invitrogen). Quantitative
reverse transcription (qRT-PCR) was performed by standard
curve method, using TaqManVR Assays probes for MRM2
(Hs00203647_m1) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (Hs99999905_m1) as a standard loading control
(Applied-Biosystem, Invitrogen).
MRM2 steady-state protein level
40lg of total protein was analyzed by electrophoresis in an SDS
12%-polyacrylamide gel, transferred onto PVDF membrane and
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probed with anti-MRM2 (1: 2000, ab60068, Abcam) and anti-
vinculin (1: 5000, Sigma) antibodies. Peroxidase-conjugated anti-
mouse IgG secondary antibodies (Santa Cruz Biotechnology)
were used at a dilution of 1: 2000 and 1: 5000, for anti-MRM2 and
anti-vinculin antibody, respectively. The protein bands were vi-
sualized by chemiluminescence (ECL, GE Healthcare).
35S-methionine metabolic labelling
To analyze translation of mitochondrially encoded proteins
metabolic labelling was performed as previously described (13).
MRM23Dmodel
The crystal structure of human MRM2 was obtained from the
Protein Data Bank (PDB ID: 2NYU). To build the structure of MRM2
harboring the p.Gly189Arg amino acid substitution, both wild-type
and mutated models were generated by SWISS-MODEL (58), using
sequence inputs based on the protein reference sequence for
MRM2 (UniProtKB: Q9UI43) (59), and 2NYU as a structural tem-
plate. Since there is no spatial information for the 50N-terminal
residues of MRM2 in the 2NYU crystal structure, these were omit-
ted in the input sequences. Global quality of the generated models
was assessed by the QMEAN Z-score, which was 1.07 for the wild-
type model and 0.77 for the p.Gly189Arg model. PyMOL (Molecular
Graphics System, Version 1.8 Schro¨dinger, LLC) was used to visual-
ize and render images from all structures.
Heterologous MRM2modeling in yeast
The yeast strains used were derived from BY4741mrm2D (MATa;
his3D1 leu2D0 met15D0 ura3D0 mrm2:: KanMX4) (EUROSCARF col-
lection). MRM2 was cloned under its natural promoter by PCR-
amplification and inserted into the pFL38 centromeric vector.
The mrm2G259R mutant allele was obtained by PCR overlap tech-
nique with appropriate primers and cloned into the pFL38 vec-
tor. The pFL38 plasmid, empty or carrying MRM2 or mrm2G259R
alleles, were introduced into the BY4741mrm2D strain.
Respiration rate was measured at 30 "C from yeast cell suspen-
sions cultured for 18h at 28 "C or for 16h at 37 "C in SC medium
supplemented with 0.6% glucose until exhaustion, using a
Clark-type oxygen electrode (Oxygraph System Hansatech
Instruments England) with 1ml of air-saturated respiration buf-
fer (0.1M phthalate–KOH, pH 5.0), 0.5% glucose. For RNA extrac-
tion, cells were suspended in extraction buffer (0.6M sorbitol,
10mM imidazole, 0.5mM EDTA, 0.1% BSA and 1mM PMSF),
were broken by vortexing on ice using glass beads and mito-
chondria were obtained by centrifugation. Then total RNA was
prepared by extraction with hot acidic phenol (60). RNA used for
RT-PEx study was extracted from an enriched mitochondrial
fraction. All experiments, except transformation, were per-
formed in synthetic complete (SC) medium (0.69% YNB without
amino acids powder, ForMedium) supplemented with 1 g/l drop-
out mix without uracil (61).
Supplementary Material
Supplementary Material is available at HMG online.
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